Firefly Neuroscience (NASDAQ:AIFF) and Pro Medicus (OTCMKTS:PMCUF) Head-To-Head Comparison

Pro Medicus (OTCMKTS:PMCUF) and Firefly Neuroscience (NASDAQ:AIFF) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Pro Medicus and Firefly Neuroscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pro Medicus	N/A	N/A	N/A
Firefly Neuroscience	-565.40%	-94.68%	-73.51%

Valuation and Earnings

This table compares Pro Medicus and Firefly Neuroscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro Medicus	N/A	N/A	N/A	N/A	N/A
Firefly Neuroscience	$1.58 million	11.82	-$19.88 million	($0.63)	-1.90

Pro Medicus has higher earnings, but lower revenue than Firefly Neuroscience.

Institutional and Insider Ownership

5.0% of Firefly Neuroscience shares are held by institutional investors. 6.9% of Firefly Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Pro Medicus and Firefly Neuroscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro Medicus	0	1	0	0	2.00
Firefly Neuroscience	1	0	0	0	1.00

Pro Medicus presently has a consensus price target of $155.00, suggesting a potential upside of 27.05%. Given Pro Medicus’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Pro Medicus is more favorable than Firefly Neuroscience.

Summary

Pro Medicus beats Firefly Neuroscience on 5 of the 8 factors compared between the two stocks.

About Pro Medicus

Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia.

About Firefly Neuroscience

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.